FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives

By The Washington Post (U.S.) | Created at 2026-08-26 19:34:45 | Updated at 2026-09-27 00:19:16 1 month ago

In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.

Donate us by clicking here.